Journal articles
Martinello M; Hajarizadeh B; Dore GJ, 2018, 'Observations on the launch of new drugs for hepatitis C', Australian Prescriber, 41, pp. 4 - 5, http://dx.doi.org/10.18773/austprescr.2018.005
Shepherd SJ; McDonald SA; Palmateer NE; Gunson RN; Aitken C; Dore GJ; Goldberg DJ; Applegate TL; Lloyd AR; Hajarizadeh B; Grebely J; Hutchinson SJ, 2018, 'HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype', Journal of Medical Virology, 90, pp. 120 - 130, http://dx.doi.org/10.1002/jmv.24919
Esmaeili A; Mirzazadeh A; Morris MD; Hajarizadeh B; Sacks HS; Maher L; Grebely J; Kim AY; Lauer G; Cox AL; Hellard M; Dietze P; Bruneau J; Shoukry NH; Dore GJ; Lloyd AR; Prins M; Page K, 2018, 'The Effect of Female Sex on Hepatitis C Incidence among People Who Inject Drugs: Results from the International Multicohort InC3 Collaborative', Clinical Infectious Diseases, 66, pp. 20 - 28, http://dx.doi.org/10.1093/cid/cix768
Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2018, 'Cover Image', Journal of Viral Hepatitis, 25, http://dx.doi.org/10.1111/jvh.12604
Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ, 2017, 'Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression', Journal of Hepatology, 67, pp. 1204 - 1212, http://dx.doi.org/10.1016/j.jhep.2017.07.025
Grebely J; Hajarizadeh B; Dore GJ, 2017, 'Direct-Acting antiviral agents for HCV infection affecting people who inject drugs', Nature Reviews Gastroenterology and Hepatology, 14, pp. 641 - 651, http://dx.doi.org/10.1038/nrgastro.2017.106
Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J, 2017, 'Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study', International Journal of Drug Policy, 47, pp. 230 - 238, http://dx.doi.org/10.1016/j.drugpo.2017.05.040
Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ, 2017, 'Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', International Journal of Drug Policy, 47, pp. 177 - 186, http://dx.doi.org/10.1016/j.drugpo.2017.05.020
Bajis S; Dore GJ; Hajarizadeh B; Cunningham EB; Maher L; Grebely J, 2017, 'Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review', International Journal of Drug Policy, 47, pp. 34 - 46, http://dx.doi.org/10.1016/j.drugpo.2017.07.002
Cunningham EB; Hajarizadeh B; Bretana NA; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Dolan K; Lloyd AR; Grebely J; Haber P; Rawlinson W; Treloar C; Maher L, 2017, 'Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study', Journal of Viral Hepatitis, 24, pp. 733 - 741, http://dx.doi.org/10.1111/jvh.12701
Hajarizadeh B; Mesgarpour B; Nasiri MJ; Alavian SM; Merat S; Poustchi H; Malekzadeh R; Sedaghat A; Haghdoost AA, 2017, 'Estimating the prevalence of hepatitis B virus infection and exposure among general population in Iran', Hepatitis Monthly, 17, http://dx.doi.org/10.5812/hepatmon.11715
Wallace J; Pitts M; Liu C; Lin V; Hajarizadeh B; Richmond J; Locarnini S, 2017, 'More than a virus: A qualitative study of the social implications of hepatitis B infection in China', International Journal for Equity in Health, 16, pp. 137, http://dx.doi.org/10.1186/s12939-017-0637-4
Grebely J; Lamoury FMJ; Hajarizadeh B; Mowat Y; Marshall AD; Bajis S; Marks P; Amin J; Smith J; Edwards M; Gorton C; Ezard N; Persing D; Kleman M; Cunningham P; Catlett B; Dore GJ; Applegate TL, 2017, 'Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study', The Lancet Gastroenterology and Hepatology, 2, pp. 514 - 520, http://dx.doi.org/10.1016/S2468-1253(17)30075-4
Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M; Conway B; Robaeys G; Swan T; Cloherty G; Marks P; Grebely J; Dore GJ; Applegate TL, 2017, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse', Journal of Clinical Virology, 92, pp. 32 - 38, http://dx.doi.org/10.1016/j.jcv.2017.05.007
Cunningham EB; Hajarizadeh B; Dalgard O; Amin J; Hellard M; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Bruneau J; Midgard H; Bourgeois S; Thurnheer MC; Dore GJ; Grebely J; Shaw I; Siriragavan S; Horschik T; Sharma S; Eevers A; Andreassen J; Melkeraaen I; Widder N; Lesneuck K; Kotsoros B; Hazelwood S; Holland R; Axten D; Von Bibra S; Powis J; Mason K; Ryder S; Jack K; Scheidegger C; Huber C; Ferguson C; Staehelin C; Lacalamita M; Fragomeli V; Sevehon A, 2017, 'Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', BMC Infectious Diseases, 17, pp. 420, http://dx.doi.org/10.1186/s12879-017-2517-3
Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2017, 'HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs', Current HIV/AIDS Reports, 14, pp. 110 - 121, http://dx.doi.org/10.1007/s11904-017-0358-8
Blach S; Zeuzem S; Manns M; Altraif I; Duberg AS; Muljono DH; Waked I; Alavian SM; Lee MH; Negro F; Abaalkhail F; Abdou A; Abdulla M; Abou Rached A; Aho I; Akarca U; Al Ghazzawi I; Al Kaabi S; Al Lawati F; Al Namaani K; Al Serkal Y; Al-Busafi SA; Al-Dabal L; Aleman S; Alghamdi AS; Aljumah AA; Al-Romaihi HE; Andersson MI; Arendt V; Arkkila P; Assiri AM; Baatarkhuu O; Bane A; Ben-Ari Z; Bergin C; Bessone F; Bihl F; Bizri AR; Blachier M; Blasco AJ; Brandao Mello CE; Bruggmann P; Brunton CR; Calinas F; Chan HLY; Chaudhry A; Cheinquer H; Chen CJ; Chien RN; Choi MS; Christensen PB; Chuang WL; Chulanov V; Cisneros L; Clausen MR; Cramp ME; Craxi A; Croes EA; Dalgard O; Daruich JR; De Ledinghen V; Dore GJ; El-Sayed MH; Ergor G; Esmat G; Estes C; Falconer K; Farag E; Ferraz MLG; Ferreira PR; Flisiak R; Frankova S; Gamkrelidze I; Gane E; Garcia-Samaniego J; Khan AG; Gountas I; Goldis A; Gottfredsson M; Grebely J; Gschwantler M; Guimaraes Pessoa M; Gunter J; Hajarizadeh B; Hajelssedig O; Hamid S; Hamoudi W; Hatzakis A; Himatt SM; Hofer H; Hrstic I; Hui YT; Hunyady B; Idilman R; Jafri W; Jahis R; Janjua NZ; Jarčuška P; Jeruma A; Jonasson JG, 2017, 'Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study', The Lancet Gastroenterology and Hepatology, 2, pp. 161 - 176, http://dx.doi.org/10.1016/S2468-1253(16)30181-9
Esmaeili A; Mirzazadeh A; Carter GM; Hajarizadeh B; Sacks HS; Page KA, 2017, 'Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis', Journal of Viral Hepatitis, 24, pp. 117 - 127, http://dx.doi.org/10.1111/jvh.12628
Hajarizadeh B; Grebely J; McManus H; Estes C; Razavi H; Gray RT; Alavi M; Amin J; McGregor S; Sievert W; Thompson A; Dore GJ, 2017, 'Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment', Journal of Gastroenterology and Hepatology (Australia), 32, pp. 229 - 236, http://dx.doi.org/10.1111/jgh.13453
Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ, 2017, 'Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014)', Hepatology Communications, 1, pp. 736 - 747, http://dx.doi.org/10.1002/hep4.1073
Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2017, 'O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', Journal of Virus Eradication, 3, pp. 5 - 5, http://dx.doi.org/10.1016/s2055-6640(20)30896-7
Alavi M; Amin J; Grebely J; Law MG; Janjua NZ; Krajden M; Hajarizadeh B; George J; Matthews GV; Larney S; Degenhardt L; Dore GJ, 2017, 'O23 Characterisation of populations with hepatitis C to improve access to antiviral therapy programs: a population-based linkage study', Journal of Virus Eradication, 3, pp. 9 - 9, http://dx.doi.org/10.1016/s2055-6640(20)30906-7
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Lloyd AR; Dore GJ, 2017, 'O6 Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the StoP-C study', Journal of Virus Eradication, 3, pp. 2 - 3, http://dx.doi.org/10.1016/s2055-6640(20)30889-x
Cunningham E; Amin J; Bretana NA; Luciani F; Degenhardt L; Larney S; Hajarizadeh B; Dore GJ; Lloyd A; Grebely J, 2017, 'P10 Injecting risk behaviours among people who inject drugs in an Australian prison setting, 2005–2014: the HITS-p study', Journal of Virus Eradication, 3, pp. 15 - 16, http://dx.doi.org/10.1016/s2055-6640(20)30751-2
Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2017, 'P20 Monitoring the uptake of hepatitis C: direct acting antiviral treatment in Australia', Journal of Virus Eradication, 3, pp. 19 - 19, http://dx.doi.org/10.1016/s2055-6640(20)30761-5
Bajis S; Lamoury F; Applegate TL; Maher L; Treloar C; Mowat Y; Schulz M; Hajarizadeh B; Marshall A; Cunningham E; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Dore GJ; Grebely J, 2017, 'P4 Acceptability of point of care finger-stick and venepuncture hepatitis C virus testing among people who inject drugs and homeless people', Journal of Virus Eradication, 3, pp. 13 - 14, http://dx.doi.org/10.1016/s2055-6640(20)30745-7
Sheridan DA; Hajarizadeh B; Fenwick FI; Matthews GV; Applegate T; Douglas M; Neely D; Askew B; Dore GJ; Lloyd AR; George J; Bassendine MF; Grebely J, 2016, 'Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection', Liver International, 36, pp. 1774 - 1782, http://dx.doi.org/10.1111/liv.13176
Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ; Han A, 2016, 'Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014)', Journal of Hepatology, 65, pp. 1086 - 1093, http://dx.doi.org/10.1016/j.jhep.2016.08.010
Alavi M; Law MG; Grebely J; Amin J; Hajarizadeh B; George J; Dore GJ; Han A, 2016, 'Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study', Journal of Hepatology, 65, pp. 879 - 887, http://dx.doi.org/10.1016/j.jhep.2016.06.025
Alavian SM; Hajarizadeh B; Lankarani KB; Sharafi H; Daryani NE; Merat S; Mohraz M; Mardani M; Fattahi MR; Poustchi H; Nikbin M; Nabavi M; Adibi P; Ziaee M; Behnava B; Rezaee-Zavareh MS; Colombo M; Massoumi H; Bizri AR; Eghtesad B; Amiri M; Namvar A; Hesamizadeh K; Malekzadeh R, 2016, 'Recommendations for the clinical management of hepatitis C in Iran: A consensus-based national guideline', Hepatitis Monthly, 16, pp. e40959, http://dx.doi.org/10.5812/hepatmon.guideline
Hajarizadeh B; Razavi-Shearer D; Merat S; Alavian SM; Malekzadeh R; Razavi H, 2016, 'Liver disease burden of hepatitis C virus infection in Iran and the potential impact of various treatment strategies on the disease burden', Hepatitis Monthly, 16, pp. e37234, http://dx.doi.org/10.5812/hepatmon.37234
Hajarizadeh B; Richmond J; Ngo N; Lucke J; Wallace J, 2016, 'Hepatitis B-related concerns and anxieties among people with chronic hepatitis B in Australia', Hepatitis Monthly, 16, pp. e35566, http://dx.doi.org/10.5812/hepatmon.35566
Lamoury FMJ; Hajarizadeh B; Keoshkerian E; Feld JJ; Amin J; Teutsch S; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Applegate TL; Grebely J; Dolan K, 2016, 'HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection', BMC Infectious Diseases, 16, pp. 241, http://dx.doi.org/10.1186/s12879-016-1567-2
Hajarizadeh B; Lamoury FMJ; Feld JJ; Amin J; Keoshkerian E; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Grebely J; Applegate TL, 2016, 'Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection', Virology Journal, 13, pp. 32, http://dx.doi.org/10.1186/s12985-016-0482-x
Hajarizadeh B; Grebely J; Martinello M; Matthews GV; Lloyd AR; Dore GJ, 2016, 'Hepatitis C treatment as prevention: evidence, feasibility, and challenges', The Lancet Gastroenterology and Hepatology, 1, pp. 317 - 327, http://dx.doi.org/10.1016/S2468-1253(16)30075-9
Bartlett SR; Jacka B; Bull RA; Luciani F; Matthews GV; Lamoury FMJ; Hellard ME; Hajarizadeh B; Teutsch S; White B; Maher L; Dore GJ; Lloyd AR; Grebely J; Applegate TL, 2016, 'HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection', Infection, Genetics and Evolution, 37, pp. 252 - 258, http://dx.doi.org/10.1016/j.meegid.2015.11.028
Gastroenterology CAO; For The Study Of The Liver CA, 2016, 'Program and Abstracts from the Canadian Digestive Diseases Week™ 2016.', Can J Gastroenterol Hepatol, 2016, pp. 4792898, http://dx.doi.org/10.1155/2016/4792898
Hajarizadeh B; Wallace J; Richmond J; Ngo N; Enright C, 2015, 'Hepatitis B knowledge and associated factors among people with chronic hepatitis B', Australian and New Zealand Journal of Public Health, 39, pp. 563 - 568, http://dx.doi.org/10.1111/1753-6405.12378
Liakina V; Hamid S; Tanaka J; Olafsson S; Sharara AI; Alavian SM; Gheorghe L; El Hassan ES; Abaalkhail F; Abbas Z; Abdou A; Abourached A; Al Braiki F; Al Hosani F; Al Jaberi K; Al Khatry M; Al Mulla MA; Al Quraishi H; Al Rifai A; Al Serkal Y; Alam A; Alashgar HI; Alawadhi S; Al-Dabal L; Aldins P; Alfaleh FZ; Alghamdi AS; Al-Hakeem R; Aljumah AA; Almessabi A; Alqutub AN; Alswat KA; Altraif I; Alzaabi M; Andrea N; Assiri AM; Babatin MA; Baqir A; Barakat MT; Bergmann OM; Bizri AR; Blach S; Chaudhry A; Choi MS; Diab T; Djauzi S; El Khoury S; Estes C; Fakhry S; Farooqi JI; Fridjonsdottir H; Gani RA; Ghafoor Khan A; Goldis A; Gottfredsson M; Gregorcic S; Hajarizadeh B; Han KH; Hasan I; Hashim A; Horvath G; Hunyady B; Husni R; Jafri W; Jeruma A; Jonasson JG; Karlsdottir B; Kim DY; Kim YS; Koutoubi Z; Lesmana LA; Lim YS; Löve A; Maimets M; Makara M; Malekzadeh R; Matičič M; Memon MS; Merat S; Mokhbat JE; Mourad FH; Muljono DH; Nawaz A; Nugrahini N; Priohutomo S; Qureshi H; Rassam P; Razavi H; Razavi-Shearer D; Razavi-Shearer K; Rozentale B; Sadik M; Saeed K; Salamat A; Salupere R; Sanai FM; Sanityoso Sulaiman A; Sayegh RA; Schmelzer JD; Sibley A, 2015, 'Historical epidemiology of hepatitis C virus (HCV) in select countries - Volume 3', Journal of Viral Hepatitis, 22, pp. 4 - 20, http://dx.doi.org/10.1111/jvh.12475
Alfaleh FZ; Nugrahini N; Matičič M; Tolmane I; Alzaabi M; Hajarizadeh B; Valantinas J; Kim DY; Hunyady B; Abaalkhail F; Abbas Z; Abdou A; Abourached A; Al Braiki F; Al Hosani F; Al Jaberi K; Al Khatry M; Al Mulla MA; Al Quraishi H; Al Rifai A; Al Serkal Y; Alam A; Alashgar HI; Alavian SM; Alawadhi S; Al-Dabal L; Aldins P; Alghamdi AS; Al-Hakeem R; Aljumah AA; Almessabi A; Alqutub AN; Alswat KA; Altraif I; Andrea N; Assiri AM; Babatin MA; Baqir A; Barakat MT; Bergmann OM; Bizri AR; Chaudhry A; Choi MS; Diab T; Djauzi S; El Hassan ES; El Khoury S; Estes C; Fakhry S; Farooqi JI; Fridjonsdottir H; Gani RA; Ghafoor Khan A; Gheorghe L; Goldis A; Gottfredsson M; Gregorcic S; Gunter J; Hamid S; Han KH; Hasan I; Hashim A; Horvath G; Husni R; Jafri W; Jeruma A; Jonasson JG; Karlsdottir B; Kim YS; Koutoubi Z; Lesmana LA; Liakina V; Lim YS; Löve A; Maimets M; Makara M; Malekzadeh R; Memon MS; Merat S; Mokhbat JE; Mourad FH; Muljono DH; Nawaz A; Olafsson S; Priohutomo S; Qureshi H; Rassam P; Razavi H; Razavi-Shearer D; Razavi-Shearer K; Rozentale B; Sadik M; Saeed K; Salamat A; Salupere R; Sanai FM; Sanityoso Sulaiman A; Sayegh RA; Schmelzer JD; Sharara AI, 2015, 'Strategies to manage hepatitis C virus infection disease burden - Volume 3', Journal of Viral Hepatitis, 22, pp. 42 - 65, http://dx.doi.org/10.1111/jvh.12474
Sibley A; Han KH; Abourached A; Lesmana LA; Makara M; Jafri W; Salupere R; Assiri AM; Goldis A; Abaalkhail F; Abbas Z; Abdou A; Al Braiki F; Al Hosani F; Al Jaberi K; Al Khatry M; Al Mulla MA; Al Quraishi H; Al Rifai A; Al Serkal Y; Alam A; Alavian SM; Alashgar HI; Alawadhi S; Al-Dabal L; Aldins P; Alfaleh FZ; Alghamdi AS; Al-Hakeem R; Aljumah AA; Almessabi A; Alqutub AN; Alswat KA; Altraif I; Alzaabi M; Andrea N; Babatin MA; Baqir A; Barakat MT; Bergmann OM; Bizri AR; Blach S; Chaudhry A; Choi MS; Diab T; Djauzi S; El Hassan ES; El Khoury S; Estes C; Fakhry S; Farooqi JI; Fridjonsdottir H; Gani RA; Ghafoor Khan A; Gheorghe L; Gottfredsson M; Gregorcic S; Gunter J; Hajarizadeh B; Hamid S; Hasan I; Hashim A; Horvath G; Hunyady B; Husni R; Jeruma A; Jonasson JG; Karlsdottir B; Kim DY; Kim YS; Koutoubi Z; Liakina V; Lim YS; Löve A; Maimets M; Malekzadeh R; Matičič M; Memon MS; Merat S; Mokhbat JE; Mourad FH; Muljono DH; Nawaz A; Nugrahini N; Olafsson S; Priohutomo S; Qureshi H; Rassam P; Razavi H; Razavi-Shearer D; Razavi-Shearer K; Rozentale B; Sadik M; Saeed K; Salamat A; Sanai FM; Sanityoso Sulaiman A; Sayegh RA; Sharara AI; Siddiq M, 2015, 'The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - Volume 3', Journal of Viral Hepatitis, 22, pp. 21 - 41, http://dx.doi.org/10.1111/jvh.12476
Sacks-Davis R; Grebely J; Dore GJ; Osburn W; Cox AL; Rice TM; Spelman T; Bruneau J; Prins M; Kim AY; Mcgovern BH; Shoukry NH; Schinkel J; Allen TM; Morris M; Hajarizadeh B; Maher L; Lloyd AR; Page K; Hellard M; Matthews G, 2015, 'Hepatitis c virus reinfection and spontaneous clearance of reinfection - The InC3 study', Journal of Infectious Diseases, 212, pp. 1407 - 1419, http://dx.doi.org/10.1093/infdis/jiv220
Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J; InC , 2015, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study', Journal of Viral Hepatitis, 22, pp. 708 - 717, http://dx.doi.org/10.1111/jvh.12384
Richmond J; Hajarizadeh B; Wallace J, 2015, 'Patients' perspectives on the delivery of hepatitis B management and care', Australian family physician, 44, pp. 346
Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Dore GJ; Grebely J, 2015, 'Patterns of hepatitis C Virus RNA levels during acute infection: The InC3 study', PLoS ONE, 10, pp. e0122232, http://dx.doi.org/10.1371/journal.pone.0122232
Hajarizadeh B; Wallace J; Richmond J; Ngo N; Enright C, 2015, 'Hepatitis B knowledge and associated factors among people with chronic hepatitis B', Australian and New Zealand Journal of Public Health, http://dx.doi.org/10.1111/1753-6405.12378
Lamoury FMJ; Bartlett S; Jacka B; Hajarizadeh B; Grebely J; Matthews GV; Dore GJ; Applegate TL, 2015, 'Interferon λ 3 and 4 genotyping using high-resolution melt curve analysis suitable for multiple clinical sample types', Journal of Molecular Diagnostics, 17, pp. 583 - 589, http://dx.doi.org/10.1016/j.jmoldx.2015.05.003
Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J; Lauer G; Shoukry NH; Hahn J; Shiboski S; Rice TM; Alavi M; Bouchard R; Aneja J; Teutsch S; White B; Wells B; Zang G; Matthews G; Marks P; Yeung B; Prince LE; Roy E; Bates A; Enriquez J; Chow S; McCredie L; Aitken C; Doyle J; Spelman T; Evans J, 2014, 'Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study', Journal of Clinical Virology, 61, pp. 430 - 434, http://dx.doi.org/10.1016/j.jcv.2014.08.027
Hajarizadeh B; Grebely J; Applegate T; Matthews GV; Amin J; Petoumenos K; Hellard M; Rawlinson W; Lloyd A; Kaldor J; Dore GJ; Dolan K, 2014, 'Dynamics of HCV RNA Levels During Acute Hepatitis C Virus Infection', Journal of Medical Virology, 86, pp. 1722 - 1729, http://dx.doi.org/10.1002/jmv.24010
Keshvari M; Pouryasin A; Behnava B; Sharafi H; Hajarizadeh B; Alavian SM, 2014, 'Letter: The rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C', Alimentary Pharmacology and Therapeutics, 39, pp. 343, http://dx.doi.org/10.1111/apt.12589
Back to profile page
https://orcid.org/0000-0003-2212-2028